摘要
目的探究化痰理气口服液对中重度慢阻肺稳定期患者肺功能和免疫功能的改善效果。方法选择2018年2月至2020年2月收治的100例中重度慢阻肺稳定期患者为研究对象,以计算机随机化法将其分为对照组(n=50)和试验组(n=50)。对照组给予布地奈德福莫特罗吸入粉雾剂,试验组在对照组的基础上给予化痰理气口服液。比较两组患者的临床疗效、治疗前、后的肺功能指标及免疫功能指标。结果试验组的治疗总有效率为96.00%,高于对照组的82.00%(P<0.05)。治疗后,两组的FEV1、FVC、FEV1/FVC、MMEF均较治疗前升高,且试验组高于对照组(P<0.05)。治疗后,两组的CD4^+、CD3^+及CD4^+/CD8^+均较治疗前升高,CD8^+较治疗前降低,且试验组优于对照组(P<0.05)。结论采用化痰理气口服液治疗中重度慢阻肺稳定期患者的效果良好,可显著改善患者的肺功能指标和免疫功能指标。
Objective To explore the improvement effect of Huatan Liqi oral liquid on pulmonary function and immune function of patients with moderate and severe chronic obstructive pulmonary disease at stable stage.Methods A total of 100 patients with moderate and severe chronic obstructive pulmonary disease at stable stage enrolled from February 2018 to February 2020 were selected as the research objects and divided into control group(n=50)and experimental group(n=50)according to the computer randomization method.The control group was given budesonide and formoterol fumarate powder for inhalation,and the experimental group was given Huatan Liqi oral liquid on the basis of the control group.The clinical efficacy,pulmonary function indexes and immune function indexes before and after treatment were compared between the two groups.Results The total effective rate of treatment in the experimental group was 96.00%,which was higher than82.00%in the control group(P<0.05).After treatment,FEV1,FVC,FEV1/FVC and MMEP of the two groups were higher than those before treatment,and those of the experimental group were higher than the control group(P<0.05).After treatment,the CD4^+,CD3^+ and CD4^+/CD8^+ in the two groups were higher than those before treatment,the CD8+was lower than that before treatment,and those in the experimental group were better than the control group(P<0.05).Conclusion Huatan Liqi oral liquid in the treatment of patients with moderate and severe chronic obstructive pulmonary disease at stable stage has good effect,which can significantly improve the pulmonary function indexes and immune function indexes of the patients.
作者
徐敏妮
刘素香
王婷霄
XU Minni;LIU Suxiang;WANG Tingxiao(Pulmonary Disease Department,Xi'an Hospital of Traditional Chinese Medicine,Xi'an 710021,China)
出处
《临床医学研究与实践》
2020年第33期140-142,共3页
Clinical Research and Practice
基金
西安市科技计划项目[No.201805103YX11SF37(6)]。
关键词
化痰理气口服液
慢性阻塞性肺疾病
肺功能
免疫功能
Huatan Liqi oral liquid
chronic obstructive pulmonary disease
pulmonary function
immune function
